TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$57 Million

Foamix Pharmaceuticals

Follow-on Offering

Bookrunner, September 2016

Foamix Pharmaceuticals
Confidentially Marketed Public Offering

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne, rosacea and other skin conditions. The Company’s lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. In September 2018, Foamix announced positive FMX101 top-line data from a third Phase III study that achieved statistical significance in both co-primary endpoints (reduction in inflammatory lesions and improvement of Investigator’s Global Assessment (IGA)) and one secondary endpoint. The Company intends to file an NDA for FMX101 in acne by YE 2018